Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Recent advances in co-delivery nanosystems for synergistic action in cancer treatment

Full text
Author(s):
Carvalho, Bruna G. [1] ; Vit, Franciele F. [1] ; Carvalho, Hernandes F. [2] ; Han, Sang W. [3] ; de la Torre, Lucimara G. [1]
Total Authors: 5
Affiliation:
[1] Univ Estadual Campinas, Sch Chem Engn, Dept Mat & Bioproc Engn, Campinas - Brazil
[2] Univ Estadual Campinas, Inst Biol, Dept Struct & Funct Biol, Campinas - Brazil
[3] Univ Fed Sao Paulo, Dept Biophys, Ctr Cell & Mol Therapy, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Review article
Source: JOURNAL OF MATERIALS CHEMISTRY B; v. 9, n. 5, p. 1208-1237, FEB 7 2021.
Web of Science Citations: 1
Abstract

Nanocarrier delivery systems have been widely studied to carry unique or dual chemical drugs. The major challenge of chemotherapies is to overcome the multidrug-resistance (MDR) of cells to antineoplastic medicines. In this context, nano-scale technology has allowed researchers to develop biocompatible nano-delivery systems to overcome the limitation of chemical agents. The development of nano-vehicles may also be directed to co-deliver different agents such as drugs and genetic materials. The delivery of nucleic acids targeting specific cells is based on gene therapy principles to replace the defective gene, correct genome errors or knock-down a particular gene. Co-delivery systems are attractive strategies due to the possibility of achieving synergistic therapeutic effects, which are more effective in overcoming the MDR of cancer cells. These combined therapies can provide better outcomes than separate delivery approaches carrying either siRNA, miRNA, pDNA, or drugs. This article reviews the main design features that need to be associated with nano-vehicles to co-deliver drugs, genes, and gene-drug combinations with efficacy. The advantages and disadvantages of co-administration approaches are also overviewed and compared with individual nanocarrier systems. Herein, future trends and perspectives in designing novel nano-scale platforms to co-deliver therapeutic agents are also discussed. (AU)

FAPESP's process: 18/18523-3 - Polymeric microparticle synthesis via droplet microfluidics for sustained release of non-viral vectors applied to gene therapy
Grantee:Bruna Gregatti de Carvalho
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 18/19537-8 - MICROFLUIDICS AS A TECHNOLOGICAL PLATFORM FOR NANO & BIOTECHNOLOGY
Grantee:Lucimara Gaziola de la Torre
Support Opportunities: Regular Research Grants
FAPESP's process: 15/20206-8 - Modulation of monocytes, macrophages and pericytes by the colony stimulating factor genes to treat murine limb ischemia
Grantee:Sang Won Han
Support Opportunities: Research Projects - Thematic Grants